The Future of Cancer Treatment: Will It Include Immunotherapy?
- Author(s): Bluestone, JA
- Small, EJ
- et al.
Published Web Locationhttps://doi.org/10.1016/j.ccr.2012.06.009
Negative immune regulatory pathways inhibit anti-cancer T cell responses, preventing effective immune surveillance. Two clinical trials using monoclonal antibodies that antagonize the PD-1/PD-L1 pathway recently reported regression in several tumor types. In one of these trials, efficacy was linked to the expression of the PD-L1 biomarker on tumor cells. © 2012 Elsevier Inc.
Many UC-authored scholarly publications are freely available on this site because of the UC Academic Senate's Open Access Policy. Let us know how this access is important for you.